Eli Lilly announced plans to file for FDA approval of retatrutide, a new weight-loss drug, following phase 3 trials where participants lost an average of nearly 56 pounds over 80 weeks. The drug targets multiple hormones affecting appetite and metabolism, potentially making it the most powerful weight loss medication available. Approval could strengthen Lilly's position in the GLP-1 market, where it already leads over Novo Nordisk. Analysts predict retatrutide could generate billions in sales by 2030-2031, highlighting strong market demand despite legal challenges from competitors.
Eli Lilly announced it will file for regulatory approval of its next-generation obesity drug, retatrutide, in the first quarter of 2027 after successful late-stage trials. The drug showed significant weight loss—up to 22.6% of body weight—and improve...
Investors seeking passive income should focus on dividend ETFs that prioritize sustainable payouts and long-term growth rather than just high yields. The Schwab U.S. Dividend Equity ETF (SCHD), Vanguard Dividend Appreciation ETF (VIG), and iShares Co...
Biotech mergers and acquisitions reached $78 billion in the first half of 2026, surpassing the entire 2025 total of $42 billion, driven by several large deals over $5 billion. Despite strong structural drivers like patent expirations and cash reserve...
Eli Lilly and Company will announce its financial results for the second quarter of 2026 on August 5. The company will hold a conference call at 10 a.m. Eastern time to discuss its performance with investors and the media, accessible via a live webca...
President Donald Trump announced that generic drugs imported into the US will continue to have zero tariffs for two more years starting August 1, 2024. After this period, tariffs will rise to 100% for one year and then 200% thereafter. The policy aim...
